HomeGreater Than Icon
Par Drugs & Chemicals LtdGreater Than Icon
Par Drugs & Chemicals Ltd Financials
Company Logo

Par Drugs & Chemicals Ltd Financial Statement

Par Drugs & Chemicals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue35.67
Operating Expense23.25
Net Profit8.60
Net Profit Margin24.11
Earning Per Share6.99
EBIDTA12.43
Effective Tax Rate23.27

Par Drugs & Chemicals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual95.64
Operating Expenses Annual72.82
Operating Profit Annual23.06
Interest Annual0.11
Depreciation3.44
Net Profit Annual14.50
Tax Annual5.02

Par Drugs & Chemicals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning22.24
Cash Flow from Operations20.25
Cash Flow from Investing-5.84
Cash Flow from FinancingTBA
Cash Flow at the End36.65

Par Drugs & Chemicals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)24.11
PBIT Margin (%)20.51
PBT Margin (%)-166.08
Net PROFIT Margin (%)15.16
Return On Networth / Equity (%)18.49
Return On Networth /Employed (%)25.01
Return On Assets (%)18.50
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)1.22

Par Drugs & Chemicals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual41.31
Total Current Assets Annual59.62
Non Current Assets Annual41.99
Total Shareholders Funds Annual85.63
Total Assets Annual101.61

Par Drugs & Chemicals Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 5, 2024, Par Drugs & Chemicals Ltd has a market capitalization of 265.10 Cr. Value Research classifies it as a Small-Cap company.
Yes, Par Drugs & Chemicals Ltd is debt-free with a debt-to-equity ratio of 0.00.
In FY 2023 , Par Drugs & Chemicals Ltd recorded a total revenue of approximately 95.64 Cr marking a significant milestone in the company's financial performance.
Par Drugs & Chemicals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.1% and 0.1% annually, respectively..
Par Drugs & Chemicals Ltd's current PE ratio is 18.28.
Par Drugs & Chemicals Ltd's ROCE averaged 22.1% from the FY ending March 2022 to 2024, with a median of 22.0%. It peaked at 22.9% in March 2024, reflecting strong capital efficiency over the period..
Par Drugs & Chemicals Ltd's latest EBIT is Rs. 19.63 Cr, surpassing the average EBIT of Rs. 16.00 Cr over the 5 years..